GlassScriptPhysician profile
Rahat H Sheikh
NPI 1750488771
$5,273.18
in general payments reported to CMS, 2019-2025
33 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $433 · 2021: $607 · 2022: $711 · 2023: $990 · 2024: $1,059 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,130.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $947.94 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $730.02 | 2020-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $475.88 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $461.41 | 2019-2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $396.20 | 2019-2025 | |
| Resmed Corp | $250.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $229.64 | 2019-2021 | |
| Daiichi Sankyo INC. | $210.89 | 2020-2024 | Injectafer |
| Lilly USA, LLC | $133.20 | 2019-2024 | Jardiance, Zepbound |
| Sanofi Pasteur INC. | $124.99 | 2021-2025 | |
| Pfizer INC. | $122.61 | 2019-2025 | |
| Exact Sciences Corporation | $117.30 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $114.33 | 2023-2025 | Vraylar |
| Medtronic, INC. | $111.09 | 2021 | |
| Dexcom, INC. | $109.12 | 2023-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $83.75 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $75.63 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $67.14 | 2022-2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $61.81 | 2022-2023 | Rexulti, Abilify Maintena |
| Genzyme Corporation | $60.00 | 2020 | |
| Horizon Therapeutics Plc | $49.97 | 2023 | Krystexxa |
| Supernus Pharmaceuticals, INC. | $48.44 | 2022 | |
| Esperion Therapeutics, INC. | $46.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.58 | 2020-2022 | |
| Seqirus USA INC | $28.27 | 2025 | Fluad, Flucelvax |
| Radius Health, INC. | $28.26 | 2019 | |
| Ironshore Pharmaceuticals INC. | $27.00 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.68 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.38 | 2021 | |
| Itamar Medical INC | $22.37 | 2024 | Watchpatone |
| Xeris Pharmaceuticals, INC. | $22.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.32 | 2025 | |
| Merck Sharp & Dohme LLC | $15.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahat Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.